China News Service, February 11th. The State Council Information Office held a regular briefing on State Council policies on the 11th. Relevant persons in charge of the National Medical Insurance Administration, the Ministry of Industry and Information Technology, the National Health and Health Commission, and the State Food and Drug Administration were responsible for deepening the concentration of drugs and high-value medical consumables. The progress of procurement reform was introduced and questions from reporters were answered.
Here are the key points you should know about this briefing!
Chen Jinfu, deputy director of the National Medical Security Administration:
——The price has returned to a reasonable level, and the masses have benefited significantly.
The first six batches of centralized procurement of medicines dropped by an average of 53%, heart stents by an average of 93%, and artificial hip joints and knee joints by an average of 82%.
The overall drug price level shows a trend of stability and decline. According to the drug price monitoring data carried out by the Medical Insurance Bureau, the overall drug price level will continue to decline in 2019 and 2021, with an average annual rate of about 7%.
Data map: Many people wait for the medicine to be taken in the medicine room.
Photo by Han Zhangyun
——The quality of drugs and consumables for clinical use has been steadily improved, and the demand for clinical services has been fully released.
From a statistical point of view, among the varieties of centralized procurement, the share of people using original research drugs and drugs that have passed the consistency evaluation of quality and efficacy has increased from 50% before centralized procurement to more than 90%.
For example, the use of imatinib in "I'm not the God of Medicine" has increased to 35% after centralized collection, so that patients in need of treatment are fully guaranteed medication.
——Consolidate the new normal, and promote the acceleration and expansion of centralized procurement.
The centralized procurement of medicines is carried out in an all-round way in the three major sectors of chemical medicines, proprietary Chinese medicines and biological medicines. High-value medical consumables focus on orthopedic consumables, drug balloons, dental implants and other varieties, and strive to purchase through national organizations and provincial alliances by the end of 2022. , to achieve an average coverage of more than 350 drug varieties per province, and more than 5 varieties of high-value medical consumables, making it a new normal for centralized procurement, so as to achieve the purpose of stabilizing social expectations and stabilizing the industry ecology.
Li Maozhong, head of the Drug Administration Department of the State Drug Administration:
——Strengthen the quality supervision of the selected drugs in the centralized procurement, list the coronary stents, artificial joints and other products selected in the centralized procurement as the focus of the quality and safety risk investigation and management in 2021, and supervise the enterprises to comprehensively investigate the hidden risks.
At the same time, unannounced inspections of manufacturers of coronary stents and artificial joints were deployed, and the inspection results were generally good.
Chen Jinfu, deputy director of the National Medical Security Administration:
——Do not pursue the lowest price, and firmly oppose running bidding, not particularly anchoring the international lowest price.
The design of competition rules actually has a mechanism for reasonable price adjustment, how to make the market discover value and make fair bidding more reasonable for enterprises.
——The policy of saving and retaining, in the case where medical institutions can rationally use drugs and give priority to use, and ensure the use of the agreed product volume, according to institutional regulations, part of the saved medical insurance funds will be retained by medical institutions to motivate doctors and solve technical labor services manifestation of value.
Wang Xuetao, head of the Pharmaceutical Administration Department of the National Health Commission:
——In the long-term prescriptions issued by doctors, doctors are encouraged to give priority to the drugs that have won the national centralized procurement.
In the performance appraisal system of the second- and third-level public hospitals, the use of the drugs that won the bids from the national centralized procurement is clearly stipulated, and the use ratio indicators are clearly defined, and the use of the national centralized procurement drugs is guided and strengthened through performance evaluation.